Protein kinase A as target for novel integrated strategies of cancer therapy

Annals of the New York Academy of Sciences

Volumn 968, Issue , 2002, Pages 139-147

  Tortora, Giampaolo ^a   Ciardiello, Fortunato ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Angiogenesis; Antisense oligonucleotides; Apoptosis; Cancer therapy; EGFR; PKA; Taxanes

Indexed keywords

8 CHLOROADENOSINE 3',5' PHOSPHATE; ANTISENSE OLIGODEOXYNUCLEOTIDE; CETUXIMAB; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; OBLIMERSEN; ORTATAXEL; PLATINUM DERIVATIVE; PROTEIN BCL 2; PROTEIN INHIBITOR; TAXANE DERIVATIVE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DNA RNA HYBRIDIZATION; HUMAN; IONIZING RADIATION; MITOGENESIS; MULTIMODALITY CANCER THERAPY; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

EID: 0036297650     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04332.x     Document Type: Conference Paper

References (45)

1. cAMP-dependent protein kinase: Role in normal and malignant growth
2. Targeting of epidermal growth factor receptor and protein kinase A: Molecular basis and therapeutic applications
3. Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa
4. Tumor cyclic AMP binding proteins: An independent prognostic factor for disease recurrence and survival in breast cancer
5. Downregulation of mdr-1 expression by 8-Cl-cAMP in multi-drug resistant MCF-7 human breast cancer cells
6. Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase
7. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth
8. Antisense oligonucleotide inhibition of serine/threonine kinases: An innovative approach to cancer treatment
9. In vivo studies with antisense oligonucleotides
10. 8-Cl-cAMP induces truncation and down-regulation of the RIα subunit and up-regulation of the RIIβ subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells
11. Downregulation of RIα subunit of the cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB2 protooncogenes
12. Overexpression of the RIα regulatory subunit of protein kinase A confers hypersensitivity to topoisomerase II inhibitors and 8-chloro-cyclic adenosine 3′, 5′ monophosphate in Chinese hamster ovary cells
13. The cAMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors
14. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A
15. Type I protein kinase a is localized to interphase microtubules and strongly associated with the mitotic spindle
16. Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells
17. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A
18. Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production
19. Antitumor activity and pharmacokinetics of a mixed-backbone oligonucleotide targeted to the RIα subunit of protein kinase A following oral administration
20. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM 231) targeting the type I protein kinase A by 2-hour infusions in patients with refractory solid tumors
21. Epidermal growth factor-related peptides and their receptors in human malignancies
22. The EGF receptor family as targets for cancer therapy
23. The RIα subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells
24. The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor
25. Site-selective 8-chloro-adenosine 3′,5′ monophosphate inhibits transformation and transforming growth factor α production in Ki-ras-transformed rat fibroblasts
26. Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector
27. Cooperative antiproliferative effects of 8-Cl-cAMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells
28. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A
29. Cooperative inhibition of renal cancer growth by anti-EGF receptor antibody and protein kinase A antisense oligonucleotide
30. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy
31. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology
32. Transforming growth factor alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP2-dependent DNA binding and transactivation
33. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo
34. Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
35. 8-Chloro-cAMP inhibits autocrine and angiogenic growth factors production in human colorectal and breast cancer
36. Dysregulation of apoptosis in cancer
37. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
38. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
39. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cAMP-dependent protein kinase
40. Novel function of the regulatory subunit of protein kinase A: Regulation of cytochrome c oxydase activity and release of cytochrome c release
41. Combined blockade of PKA and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis
42. Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide
43. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor
44. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth
45. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity